BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19570738)

  • 1. Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome.
    Pacak K; Eisenhofer G; Ilias I
    Hormones (Athens); 2009; 8(2):111-6. PubMed ID: 19570738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis, localization and treatment of pheochromocytoma in MEN 2 syndrome.
    Ilias I; Pacak K
    Endocr Regul; 2009 Apr; 43(2):89-93. PubMed ID: 19856714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome.
    Kaji P; Carrasquillo JA; Linehan WM; Chen CC; Eisenhofer G; Pinto PA; Lai EW; Pacak K
    Eur J Endocrinol; 2007 Apr; 156(4):483-7. PubMed ID: 17389464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas.
    Taïeb D; Tessonnier L; Sebag F; Niccoli-Sire P; Morange I; Colavolpe C; De Micco C; Barlier A; Palazzo FF; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):580-6. PubMed ID: 18394015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
    Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
    Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
    Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
    Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
    Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
    J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 123I-MIBG, 18F-DOPA and 18F-FDG in a patient with MEN2 syndrome and recurrent pheochromocytoma.
    Cuenca-Cuenca JI; Marín-Oyaga VA; Borrego-Dorado I; Navarro-González E; Martos-Martínez JM; Vázquez-Albertino R
    Rev Esp Med Nucl Imagen Mol; 2013; 32(4):263-5. PubMed ID: 23434017
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Jazbec T; Girod PP; Url C; Thomé C; Riechelmann H; Sprinzl GM; Fraedrich G; Virgolini IJ
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):94-99. PubMed ID: 30630744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study.
    Blanchet EM; Taieb D; Millo C; Martucci V; Chen CC; Merino M; Herscovitch P; Pacak K
    J Nucl Med; 2015 Dec; 56(12):1849-54. PubMed ID: 26359261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma.
    Taïeb D; Jha A; Guerin C; Pang Y; Adams KT; Chen CC; Romanet P; Roche P; Essamet W; Ling A; Quezado MM; Castinetti F; Sebag F; Pacak K
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1574-1582. PubMed ID: 29534198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warburg effect's manifestation in aggressive pheochromocytomas and paragangliomas: insights from a mouse cell model applied to human tumor tissue.
    Fliedner SM; Kaludercic N; Jiang XS; Hansikova H; Hajkova Z; Sladkova J; Limpuangthip A; Backlund PS; Wesley R; Martiniova L; Jochmanova I; Lendvai NK; Breza J; Yergey AL; Paolocci N; Tischler AS; Zeman J; Porter FD; Lehnert H; Pacak K
    PLoS One; 2012; 7(7):e40949. PubMed ID: 22859959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review.
    Rufini V; Treglia G; Castaldi P; Perotti G; Giordano A
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):122-33. PubMed ID: 23822989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.
    Ilias I; Chen CC; Carrasquillo JA; Whatley M; Ling A; Lazúrová I; Adams KT; Perera S; Pacak K
    J Nucl Med; 2008 Oct; 49(10):1613-9. PubMed ID: 18794260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
    Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.